

NEOVASC INC
Form SC 13G/A
February 14, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-1(b), (c)
AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)*

Neovasc Inc.
(Name of Issuer)
Common Stock, without par value
(Title of Class of Securities)

64065J106
(CUSIP Number)

December 31, 2018
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to *the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Schedule 13G

CUSIP No. 64065J106 PAGE 2 of 6

NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

(1) OPKO Health, Inc.
75-2402409

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(2) (a) " (b) "

(3) SEC USE ONLY

CITIZENSHIP OR PLACE OF ORGANIZATION

(4) Delaware

(5) SOLE VOTING POWER
Common Shares*

NUMBER 3,361,298 Series A Warrants to purchase up to 28,770 Common Shares (see Item 4)*

OF (6) SHARED VOTING POWER
SHARES 0

BENEFICIALLY (7) SOLE DISPOSITIVE POWER
OWNED

BY EACH Common Shares*
REPORTING PERSON 3,361,298 Series A Warrants to purchase up to 28,770 Common Shares (see Item 4)*

WITH (8) SHARED DISPOSITIVE POWER

(8) 0

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

(9) Common Shares*
3,361,298 Series A Warrants to purchase up to 28,770 Common Shares (see Item 4)*

(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES "

(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
9.1%

(12) TYPE OF REPORTING PERSON
CO

*See Item 4 below.

Schedule 13G

CUSIP No. 64065J106 PAGE 3 of 6

ITEM 1(a). NAME OF ISSUER:

Neovasc Inc.

ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

Suite 5138 - 13562 Maycrest Way

Richmond, British Columbia, Canada V6V 2J7

ITEMS 2(a), 2(b) and 2(c). NAME OF PERSON FILING, ADDRESS OF PRINCIPAL BUSINESS OFFICE AND CITIZENSHIP:

(a) Name of Person filing: OPKO Health, Inc. (the "Company")

(b) Address of Principal Business Office: 4400 Biscayne Blvd., Miami, FL 33137

(c) Citizenship: Delaware

ITEM 2(d). TITLE OF CLASS OF SECURITIES: Common Shares, without par value

ITEM 2(e). CUSIP NUMBER: 64065J106

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

(a) " Broker or dealer registered under Section 15 of the Act;

(b) " Bank as defined in Section 3(a)(6) of the Act;

(c) " Insurance Company as defined in Section 3(a)(19) of the Act;

(d) " Investment Company registered under Section 8 of the Investment Company Act of 1940;

(e) .. Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E);

(f) .. Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F);

(g) " Parent Holding Company, in accordance with Rule 13d- 1(b(ii)(G);

(h) " Savings Associations as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i) .. Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940;

(j) " Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Schedule 13G

CUSIP No. 64065J106 PAGE 4 of 6

ITEM 4. OWNERSHIP.

(a) Amount beneficially owned:

3,361,298 Common Shares

Series A Warrants to purchase up to 28,770 Common Shares*

(b) Percent of class: 9.1%**

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:

3,361,298 Common Shares

Series A Warrants to purchase up to 28,770 Common Shares*

(ii) shared power to vote or to direct the vote: 0

(iii) sole power to dispose or to direct the disposition of:

3,361,298 Common Shares

Series A Warrants to purchase up to 28,770 Common Shares*

(iv) shared power to dispose or to direct the disposition of: 0

The Company holds 28,770 Series A Warrants (the "Warrants"), 20,548 of which were issued pursuant to a public offering. The Company received the remaining Warrants which are exercisable into 8,222 Common Shares as a result of the exercise of its Series C Warrant. The Warrants are currently exercisable and contain terms that prohibit the Company from exercising any portion of such Warrants if doing so would result in the Company (together with *certain affiliates) beneficially owning more than 9.99% of the number of Common Shares of the Issuer outstanding immediately after giving effect to its exercise of such portion. The amount of Common Shares set forth in sub clauses (a) and (c) above and on Rows (5), (7) and (9) of the cover page for the Company show the number of Common Shares that would be issuable upon full exercise of the Warrants (without giving effect to certain anti-dilution provisions contained in the Warrants).

As of February 13, 2019, the total number of issued and outstanding Common Shares of the Issuer was 37,025,089, ** which was provided by the Issuer. On September 18, 2018, the Issuer effected a 1 for 100 reverse stock split of its issued and outstanding Common Shares. All references in the SC 13G amendment to Common Shares and warrants have been adjusted reflect the reverse split.

The Common Shares held by the Company do not include securities owned by Frost Gamma Investment Trust ("FGIT"), an affiliate of Phillip Frost, MD ("Dr. Frost"), the Company's Chairman and Chief Executive Officer. FGIT holds 1,168,024 Common Shares and Series A warrants to purchase 19,180 Common Shares. Dr. Frost is the sole trustee of FGIT. The Company disclaims beneficial ownership of the securities of the Issuer beneficially owned by FGIT and Dr. Frost.

In connection with undertakings made to the Securities and Exchange Commission, as part of a previously announced settlement, the Company is evaluating all of its strategic minority investments and reporting under Section 13(d) of the Exchange Act. In connection with this evaluation, the Company may make additional or amended filings pursuant to Section 13(d) and/or Section 13(g) of the Exchange Act reflecting group membership.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: N/A

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY: N/A

Schedule 13G

CUSIP No. 64065J106 PAGE 5 of 6

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: N/A

ITEM 9. NOTICE OF DISSOLUTION OF GROUP: N/A

ITEM 10. CERTIFICATION. (if filing pursuant to Rule 13d-1(c))

The Reporting Person hereby makes the following certification:

By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Schedule 13G

CUSIP No. 64065J106 PAGE 6 of 6

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: February 14, 2019

/s/ Kate Inman

OPKO Health, Inc.

By: Kate Inman, General Counsel, Secretary